ASC’s Webinar Series: TARGATT™: A Key Technology to Enable Efficient Antibody/Protein Discovery, Expression and Bioproduction | ASC

Applied StemCell is putting forth a new webinar highlighting its top-selling research tools using its proprietary TARGATT™ technology to aid in building large mammalian cell libraries and for protein evolution studies for antibody discovery, screening, and bioproduction applications.

Title: TARGATT™ Rapid and Efficient Transgene Integration Technology: Stable Cell Line Development and Generation of Large Mammalian Cell-based Screening Libraries

Presenter: Xiuling Chi, PhD

The webinar covers the following topics:

• importance of mammalian screening libraries and advantages of integrase for transgene insertion

• TARGATT™ technology for site-specific gene knock-in,

• TARGATT™ Master Cell Line for transgene knock-in

• Evaluation of various docking site (landing pad) loci for high level protein expression

• Expression of a Fc fusion protein

• Potential applications for the TARGATT™ mammalian library screens.

This webinar is suitable for researchers involved in:

• Protein evolution studies

• Antibody discovery and screening

• Mammalian two-hybrid (M2H) screens

• AAV/viral vector capsid screening

• And, more

Applied StemCell's TARGATT™ site-specific transgene knock-in technology provides a very efficient platform for stable cell line generation and for mammalian cell-based library screening. Based on our very successful TARGATT™ transgenic mouse model generation platform, the TARGATT™ Master Cell Lines in the HEK293, CHO, and iPSC backgrounds have been engineered to carry an integrase recognition landing pad, "attP" in a preselected, intergenic, safe harbor locus (such as the H11 or our proprietary ASC2 locus). These master cell lines enable very efficient, single copy integration of transgene(s) into these well-characterized loci without disruption of internal genes and copy number induced silencing.

For more details, explore our website or contact us at info@appliedstemcell.com.

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

More information can be found at www.appliedstemcell.com.

Media Contact:

Maki Ogawa

Marketing Director, Applied StemCell, Inc.

408-773-8007

maki.ogawa@appliedstemcell.com